(AEZS) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
May 22, 2013
(Stock Blog Hub,
1/5/13)
Aeterna Zentaris Inc. (AEZS) recently announced that its oncology candidate, AEZS-108 (doxorubicin peptide conjugate) will be evaluated under US...(read more)
(Wall Street Sector Selector,
3/9/11)
Active traders and day traders have many stocks to choose from this Wednesday morning. We are tracking news and moves in shares of AEterna Zentaris, Inc. (NASDAQ: AEZS), Finisar, Inc. (NASDAQ: FNSR), JDS Uniphase Corporation (NASDAQ: JDSU), and O...
(Penny Stock DD,
12/5/10)
Many of those who purchased at $1.15 per share following my September 17th article have sent me inquiries about my current view on AEterna Zentaris (AEZS) and where to sell AEZS. AEZS is currently $1.54 per share, which represents nearly a 34% gain in the past 10 weeks. Some may have locked [...]
AEterna Zentaris (AEZS) Company Overview
There is no analysis for AEZS yet. But you can go to Wikinvest to help create one!
